Acceleron Pharma Inc (XLRN) CFO Sells $814,910.00 in Stock

Acceleron Pharma Inc (NASDAQ:XLRN) CFO Kevin F. Mclaughlin sold 19,000 shares of the business’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $42.89, for a total transaction of $814,910.00. Following the sale, the chief financial officer now owns 45,300 shares in the company, valued at approximately $1,942,917. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Acceleron Pharma Inc (NASDAQ XLRN) opened at $42.11 on Friday. Acceleron Pharma Inc has a 52-week low of $23.07 and a 52-week high of $44.80. The firm has a market capitalization of $1,942.39, a PE ratio of -16.26 and a beta of 1.59.

Acceleron Pharma (NASDAQ:XLRN) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.52 million. During the same quarter in the previous year, the firm earned ($0.55) EPS. Acceleron Pharma’s revenue was up .0% on a year-over-year basis. analysts anticipate that Acceleron Pharma Inc will post -2.65 earnings per share for the current year.

A number of large investors have recently modified their holdings of the business. BlackRock Inc. raised its position in Acceleron Pharma by 9.0% in the 2nd quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock worth $121,719,000 after buying an additional 330,635 shares during the last quarter. Vanguard Group Inc. raised its position in Acceleron Pharma by 6.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,029,040 shares of the biopharmaceutical company’s stock worth $61,663,000 after buying an additional 116,705 shares during the last quarter. Westfield Capital Management Co. LP raised its position in Acceleron Pharma by 46.6% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock worth $51,127,000 after buying an additional 534,440 shares during the last quarter. Perceptive Advisors LLC raised its position in Acceleron Pharma by 127.2% in the 3rd quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock worth $60,319,000 after buying an additional 905,000 shares during the last quarter. Finally, State Street Corp raised its position in Acceleron Pharma by 9.4% in the 2nd quarter. State Street Corp now owns 1,131,824 shares of the biopharmaceutical company’s stock worth $34,386,000 after buying an additional 97,199 shares during the last quarter. 85.70% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have recently commented on XLRN. HC Wainwright restated a “buy” rating and set a $62.00 target price on shares of Acceleron Pharma in a report on Monday, December 11th. Oppenheimer reaffirmed a “hold” rating on shares of Acceleron Pharma in a research report on Wednesday, September 20th. BidaskClub raised Acceleron Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Royal Bank of Canada reaffirmed a “hold” rating on shares of Acceleron Pharma in a research report on Thursday, November 2nd. Finally, Credit Suisse Group set a $51.00 price target on Acceleron Pharma and gave the stock a “buy” rating in a research report on Tuesday, November 14th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $44.56.

TRADEMARK VIOLATION WARNING: This news story was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2018/01/07/acceleron-pharma-inc-xlrn-cfo-sells-814910-00-in-stock.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit